Free tool
FAERS Monitor: Methyldopa
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 018934 or its brand name (Methyldopa, Methyldopa). Reports on generic versions are filed under their own applications.
Reports
4,936
Serious
4,615
93% of reports
Hospitalization
1,654
Death reported
231
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- foetal exposure during pregnancy1,364
- premature baby930
- maternal exposure during pregnancy838
- exposure during pregnancy698
- premature delivery584
- low birth weight baby389
- drug ineffective268
- hypertension259
- off label use231
- foetal growth restriction216
- pre-eclampsia208
- atrial septal defect196
- dyspnoea195
- caesarean section168
- live birth165
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 37 |
| 2005 | 71 |
| 2006 | 63 |
| 2007 | 60 |
| 2008 | 99 |
| 2009 | 127 |
| 2010 | 112 |
| 2011 | 161 |
| 2012 | 161 |
| 2013 | 166 |
| 2014 | 253 |
| 2015 | 198 |
| 2016 | 219 |
| 2017 | 245 |
| 2018 | 468 |
| 2019 | 431 |
| 2020 | 393 |
| 2021 | 346 |
| 2022 | 329 |
| 2023 | 257 |
| 2024 | 305 |
| 2025 | 199 |
| 2026 | 236 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,223 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| low birth weight babySignal | 389 | 219.3 | 198.8 | 80,213 |
| pre-eclampsiaSignal | 208 | 195.0 | 170.2 | 38,211 |
| premature deliverySignal | 584 | 162.2 | 150.0 | 90,028 |
| foetal growth restrictionSignal | 216 | 156.9 | 137.4 | 32,135 |
| premature babySignal | 930 | 135.8 | 128.0 | 120,671 |
| atrial septal defectSignal | 196 | 102.1 | 88.9 | 19,070 |
| live birthSignal | 165 | 85.7 | 73.7 | 13,463 |
| foetal exposure during pregnancySignal | 1,364 | 72.7 | 69.5 | 95,140 |
| caesarean sectionSignal | 168 | 62.3 | 53.7 | 9,939 |
| exposure during pregnancySignal | 698 | 48.4 | 45.2 | 32,076 |
| maternal exposure during pregnancySignal | 838 | 40.4 | 38.0 | 32,024 |
| hypertensionSignal | 259 | 5.2 | 4.6 | 886 |
| dyspnoea | 195 | 1.5 | 1.3 | 29 |
| off label use | 231 | 1.1 | 1.0 | 3 |
| drug ineffective | 268 | 0.9 | 0.8 | 6 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.